Introduction {#Sec1}
============

Cardiovascular disease (CVD) is the leading cause of death among dialysis patients. Many uremia-associated factors are involved in the high cardiovascular mortality and morbidity \[[@CR1]\]. Clinical and experimental studies showed that phosphate (P) overload plays a pivotal role in CVD development in uremic patients. In fact, hyperphosphatemia is significantly associated with mortality and cardiovascular events (CVEs) among chronic kidney disease (CKD) patients receiving or not receiving dialysis \[[@CR2]--[@CR4]\]. Vascular calcification is also a likely predictor of mortality and CVEs \[[@CR5], [@CR6]\]. The pathomechanism underlying vascular calcification in uremia remains obscure, but the transition of vascular smooth muscle cells into osteoblast-like cells promoted by P and calcium (Ca) overload is considered to be an important step \[[@CR7], [@CR8]\].

Traditionally, Ca-based P binders, including calcium carbonate (CC) and calcium acetate (CA), have been widely used in clinical settings. However, it has been indicated that Ca-based P binder use might promote vascular calcification through positive Ca balance, which might lead to increased mortality and CVEs. In a meta-analysis of 11 randomized control trials (RCTs) in hemodialysis patients, patients receiving non-Ca-based P binders had a 22 % reduction in all-cause mortality compared to those receiving Ca-based P binders \[[@CR9]\]. However, individual RCTs have not always demonstrated clear superiority of non-Ca-based P binders over Ca-based P binders for reducing mortality and CVEs \[[@CR10]--[@CR20]\]. Thus, so far, there is no obvious evidence that non-Ca-based P binders improve mortality and CVEs in dialysis patients. Lanthanum carbonate (LC), which is a non-Ca-based P binder, has been clinically available since 2009 in Japan. LC effectively decreases serum P concentration with a lower incidence of hypercalcemia in hyperphosphatemic patients on regular hemodialysis \[[@CR21], [@CR22]\]. In addition, small-scale RCTs have demonstrated that LC slows progression of aortic calcification compared to that with CC in chronic hemodialysis patients \[[@CR23], [@CR24]\]. The LANDMARK (outcome study of lanthanum carbonate compared with calcium carbonate on cardiovascular mortality and morbidity in patients with chronic kidney disease on hemodialysis) study was planned to elucidate whether LC treatment reduces CVD mortality and morbidity compared to that with CC treatment in regular hemodialysis patients. In addition, we performed a subsidiary study (LANDMARK-SS) in which progression of coronary artery calcification (CAC) was compared between groups in enrolled patients undergoing multi-detector row computed tomography.

Materials and methods {#Sec2}
=====================

Study design {#Sec3}
------------

The LANDMARK study is a multicenter, randomized, open-label, parallel comparative study conducted among outpatients on regular hemodialysis. The study protocol and informed consent form were approved by the institutional review boards of each center. Written informed consent for participation was obtained from each patient. This study is being conducted in accordance with the Declaration of Helsinki and the Ethical Guideline on Clinical Studies by the Ministry of Health, Labour and Welfare of Japan. The study has been registered with ClinicalTrials.gov (NCT01578200) and umin.ac.jp (UMIN000006815).

Study patients {#Sec4}
--------------

The current study enrolled patients who had been on hemodialysis for at least 3 months and required P binder therapy. All patients had at least one vascular calcification risk factor \[elderly (≥65 years), postmenopausal woman, or type 2 diabetes mellitus\] with intact parathyroid hormone (iPTH) ≤240 pg/mL and life expectancy ≥1 year. Diabetes mellitus was defined as: (1) fasting plasma glucose level ≥126 mg/dL (7.0 mmol/L), (2) random plasma glucose level or 2-h plasma glucose value in a 75 g oral glucose tolerance test ≥200 mg/dL (11.1 mmol/L), (3) hemoglobin A1c (HbA1c, NGSP: National Glycohemoglobin Standardization Program) ≥6.5 %, or (4) the use of antidiabetes medication.

Patients were excluded if (1) they were undergoing peritoneal dialysis, (2) they had contraindications to LC or CC, swallowing disorders, severe gastrointestinal disorders, history of bowel obstruction, history of ischemic heart disease/stroke within the previous 6 months, New York Heart Association (NYHA) classification III--IV heart failure, arrhythmia requiring treatment, severe liver dysfunction, severe malnutrition, or malignancy within 5 years, (3) they were pregnant or possibly pregnant or lactating and/or planned to be pregnant within the study term, or (4) they were ineligible according to the investigator's judgment.

Patients were enrolled between November 2011 and June 2014 from 273 centers across the country. Although the planned enrollment period had been initially 2 years, it was extended by 8 months due to insufficient accrual of patients. Patient follow-up is ongoing and will end in June 2017. To explore the effect of LC on the coronary artery, an imaging subsidiary study focusing on coronary calcification using multidetector computed tomography (Agatston score) is concurrently in progress (UMIN000006816). The details of the subsidiary study will be reported elsewhere.

Interventions {#Sec5}
-------------

Study drugs were administered within 14 days after registration and continued until 3 years after the last patient registration. Patients assigned to the LC group initially received an oral dose of 750 mg/day (3 times immediately after meals) or the previously used dose. To achieve P levels of 3.5--6 mg/dL, patients were titrated up to a maximum of 2250 mg/day. Titration intervals were longer than a week, and the dose increased by \<750 mg/day. If the P level was not achieved with 2250 mg/day or the maximum tolerated dose, sevelamer hydrochloride or non-Ca-based P binders could be added. CC was prohibited in the LC group.

Patients assigned to the CC group received an oral dose of 3 g/day (3 times immediately after meals) or the previously used dose. To achieve the desired P levels, patients were titrated. If the P level was not achieved with the maximum tolerated dose, sevelamer hydrochloride or non-Ca-based P binders could be added. LC was prohibited in the CC group.

Outcomes {#Sec6}
--------

The primary endpoint is the CVE-free survival. CVEs consisted of (1) death due to CVD (myocardial infarction or stroke), including sudden cardiac death (International Classification of Diseases: ICD-10 codes R96.0/96.1), (2) non-fatal myocardial infarction, (3) non-fatal stroke, including transient ischemic attack (TIA), (4) unstable angina, (5) hospitalization for heart failure (HF), and (6) hospitalization for ventricular arrhythmia. CVE-free survival was defined as the time from the date of the first administration to the date of the first documented CVE.

The secondary endpoints include overall survival, secondary hyperparathyroidism-free survival, hip fracture-free survival, and adverse drug reactions. Adverse drug reactions (other than efficacy end-point components) are collected until 30 days after completion of the protocol treatment if the investigators cannot deny a causal relationship between the investigational drugs and the adverse events. The quality of life questionnaire (kidney disease quality of life short form: KDQOL-SF, v1.3) and bone mineral density by dual energy X-ray absorptiometry are examined at selected institutes.

Myocardial infarction is defined as chest symptoms consistent with myocardial ischemia lasting more than 30 min, suspected/definite electrocardiographic changes indicative of ischemia in at least 2 contiguous leads, and cardiac biomarker elevation. Stroke is defined by imaging (computed tomography or magnetic resonance imaging) evidence of cerebral focal ischemia in a defined vascular distribution. Strokes are classified into ischemic or hemorrhagic stroke. Transient ischemic attack is defined as a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia without acute infarction \[[@CR25]\]. Unstable angina is defined according to a previous report \[[@CR26]\]. HF hospitalization is defined as an event that meets: admission with a primary diagnosis of HF, new or worsening symptoms due to HF, and diagnostic evidence, such as echocardiography. Secondary hyperparathyroidism is defined as iPTH \>240 pg/mL. Hip fracture due to high-energy trauma is not an endpoint.

Sample size {#Sec7}
-----------

Based on the Japanese Society for Dialysis Therapy, the annual crude mortality of Japanese patients on dialysis was 9.7 % in 2010 \[[@CR27]\]. The cardiovascular mortality was 3.9 %, and the cardiovascular non-fatal event rate was estimated as 3.9 %. Therefore, estimated annual CVE rate was 7.8 %. Based on the assumptions of a hazard ratio of 0.8, two-tailed alpha of 0.05, and 80 % power, 1231 subjects were required for each group. Taking into consideration a 10 % drop-out rate, the sample size was set to be 1500 for each group and 3000 overall.

Randomization {#Sec8}
-------------

The patients were enrolled through a web-based registration and follow-up system provided by the data center at the Translational Research Informatics Center, Kobe, Japan. After obtaining the informed consent from each patient, the primary physician was allowed to access to the system for sending the information required for enrollment. The system automatically evaluated the eligibility of each patient and randomly assigned participants to either the LC group or CC group (1:1 allocation). When allocation was performed, age (\<65 years old vs. not), sex (female vs. male), diabetes (absence vs. presence), and site were dynamically balanced between the two groups.

Statistical analyses {#Sec9}
--------------------

The safety analysis comprised the data from eligible patients who received at least one dose of the study drug. The full analysis set comprised the data from patients who received at least one dose of the study drug, met all inclusion criteria, and did not meet any exclusion criterion. This will be the primary analysis set for the efficacy endpoints. The per protocol set comprised the data from patients who received at least one dose of the study drug, met all inclusion criteria, did not meet any exclusion criterion, and had no major protocol violations.

The cumulative incidences of events will be estimated using the Kaplan--Meier method. Two treatment groups will be compared using the log-rank test. As for the quality of life and the bone mineral density tests, patterns of change in each parameter over time and how the patterns differed between the two treatment groups will be investigated using linear mixed effects models. The model will include the treatment group and time as fixed effects and patient as a random effect. In the safety analysis set, incidences of adverse events will be compared between the two groups using a Fisher's exact test. All analyses will be performed using the SAS software version 9.3 (Cary, NC, USA), and the level of significance is *P* \< 0.05 (two-tailed).

Results {#Sec10}
=======

In the current study, 2309 patients in 273 participating centers were enrolled from November 2011 to June 2014. Of these, 236 patients were enrolled for the concurrent imaging subsidiary study on CAC. The 2309 patients were randomly allocated to the LC group (1154 patients) or CC group (1155 patients). However, due to ineligibility found after randomization, consent withdrawal, or overlapped registration, 18 patients in the LC group and 24 in the CC group were excluded from the study. In addition, 45 patients did not take LC in the LC group, and 38 patients did not take CC in the CC group.

The baseline characteristics of the patients are shown in Table [1](#Tab1){ref-type="table"}. The average age of patients was 68.4 years old, and 59.6 % of the subjects were male. Almost all patients (94.8 %) had previously received P binders, and 30.8 % had previously taken LC. The primary causes of CKD were diabetes (49.5 %) and glomerulonephritis (22.8 %). A history of ischemic heart disease and cerebrovascular disease was seen in 18.3 and 13.9 % of patients, respectively.Table 1Baseline characteristics (*n* = 2184)Total (*n* = 2184)Lanthanum carbonate (*n* = 1091)Calcium carbonate (*n* = 1093)Male1301 (59.6)652 (59.8)649 (59.4)Age (years)68.4 ± 9.668.3 ± 9.768.4 ± 9.5Body weight (kg)56.3 ± 12.056.3 ± 11.556.3 ± 12.4Body mass index (kg/m^2^)22.0 ± 3.722.0 ± 3.622.0 ± 3.8Previous treatment Calcium carbonate1617 (78.1)784 (76.3)833 (79.8) Lanthanum carbonate637 (30.8)341 (33.2)296 (28.4) Sevelamer hydrochloride433 (20.9)212 (20.6)221 (21.2) Oral vitamin D1466 (67.1)742 (68.0)724 (66.2) RAS inhibitor934 (42.8)470 (43.1)464 (42.5)Primary cause of CKD Diabetes1082 (49.5)548 (50.2)534 (48.9) Glomerulonephritis499 (22.8)257 (23.6)242 (22.1) Hypertensive nephrosclerosis254 (11.6)119 (10.9)135 (12.4) Polycystic kidney disease88 (4.0)46 (4.2)42 (3.8) Pyelonephritis19 (0.9)8 (0.7)11 (1.0) Other242 (11.1)113 (10.4)129 (11.8)Comorbidity Hypertension1771 (81.1)881 (80.8)890 (81.4) Diabetes1221 (55.9)607 (55.6)614 (56.2) Dyslipidemia558 (25.5)296 (27.1)262 (24.0) Peripheral artery disease343 (15.7)169 (15.5)174 (15.9) Anemia1745 (79.9)896 (82.1)849 (77.7)Past medical history Ischemic heart disease400 (18.3)204 (18.7)196 (17.9)  Myocardial infarction98 (4.5)49 (4.5)49 (4.5)  Unstable angina121 (5.5)54 (4.9)67 (6.1)  Coronary intervention184 (8.4)101 (9.3)83 (7.6) Cerebrovascular disease304 (13.9)150 (13.7)154 (14.1)  Ischemic stroke212 (9.7)108 (9.9)104 (9.5)  Hemorrhagic stroke72 (3.3)32 (2.9)40 (3.7)  Transient ischemic attack32 (1.5)13 (1.2)19 (1.7) Heart failure202 (9.2)99 (9.1)103 (9.4) Ventricular arrhythmia39 (1.8)15 (1.4)24 (2.2) Secondary hyperparathyroidism880 (40.3)422 (38.7)458 (41.9) Smoking258 (11.8)124 (11.4)134 (12.3)Data are presented as n (%), or mean ± standard deviation*CKD* chronic kidney disease, *RAS inhibitor* renin-angiotensin inhibitor

In addition, most patients (98.1 %) underwent dialysis 3 days per week for 4 h per day (Table [2](#Tab2){ref-type="table"}). Hemodialysis was most frequently used technique (89.7 %). Mean serum Ca, P, and iPTH concentrations were 8.9 mg/dL, 5.3 mg/dL, and 122 pg/mL, respectively. Baseline characteristics were well balanced between the two groups, except for the proportion of other P binder use.Table 2Procedural and laboratory data (*n* = 2184)Total (*n* = 2184)Lanthanum carbonate (*n* = 1091)Calcium carbonate (*n* = 1093)Hemodialysis Frequency (3 sessions/week)2143 (98.1)1068 (97.9)1075 (98.4) Dialysis time (h/session)4.0 ± 0.54.0 ± 0.54.0 ± 0.5 Dialysate calcium (mEq/L)2.8 ± 0.62.8 ± 0.52.8 ± 0.6Hemodialysis techniques Hemodialysis1960 (89.7)979 (89.7)981 (89.8) Online hemodiafiltration172 (7.9)83 (7.6)89 (8.1) Hemodiafiltration53 (2.4)31 (2.8)22 (2.0)Initial dose Lanthanum carbonate (mg/day)--997.7 ± 528.1-- Calcium carbonate (g/day)----2.3 ± 1.2Other phosphate binder use531 (24.3)216 (19.8)315 (28.8)Laboratory data Serum albumin (g/dL)3.7 ± 0.43.7 ± 0.43.7 ± 0.4 Blood urea nitrogen (mg/dL)62.0 ± 14.062.0 ± 14.162.1 ± 14.0 Serum creatinine (mg/dL)10.3 ± 2.310.3 ± 2.310.2 ± 2.4 Serum calcium (mg/dL)8.9 ± 0.78.8 ± 0.78.9 ± 0.7 Corrected calcium (mg/dL)9.2 ± 0.79.1 ± 0.79.2 ± 0.7 Serum phosphorus (mg/dL)5.3 ± 1.35.3 ± 1.45.3 ± 1.3 Intact parathyroid hormone (pg/mL)122.4 ± 79.4126.8 ± 86.6117.9 ± 71.1*K* ~t~/*V*1.55 ± 0.351.54 ± 0.361.55 ± 0.33nPCR (g/kg/day)0.94 ± 0.180.94 ± 0.180.94 ± 0.18Data are presented as *n* (%), or mean ± standard deviation*K* ~t~/*V* = −ln(*C* ~e~/*C* ~s~ − 0.008 **×** *t* ~d~) + (4--3.5 **×** *C* ~e~/*C* ~s~) **×** ΔBW/BW, where *C* ~s~: before dialysis BUN, *C* ~e~: after dialysis BUN, *t* ~d~: dialysis duration (h), ΔBW: change of body weight before and after dialysis, BW: after dialysis body weightnPCR = *C* ~0~/(36.3 + 5.48 **×** *K* ~t~/*V* + 53.5/*K* ~t~/*V*) + 0.168, where *C* ~0~: before dialysis BUN*nPCR* normalized protein catabolic rate

Discussion {#Sec11}
==========

Observational studies have shown that an increment of P burden deteriorates mortality and the CVE frequency among dialysis patients \[[@CR1], [@CR8], [@CR28]--[@CR30]\]. Therefore, nephrologists have sought to achieve optimal P management. In addition to their tolerability, Ca-based P binders are inexpensive and very effective in reducing serum P concentration \[[@CR31], [@CR32]\]. However, administration of Ca-based P binders evokes Ca overload, which are likely to accelerate vascular calcification, thereby potentially leading to increased morality and the CVE frequency \[[@CR33]--[@CR36]\]. Although a meta-analysis suggested that non-Ca-based P binders are associated with a decreased risk of all-cause mortality compared with Ca-based P binders in CKD patients, individual study demonstrated that non-Ca-based P binders have not always been shown to improve mortality and/or to slow the progression of vascular calcification, probably because of the small numbers of study patients and outcome events \[[@CR9]--[@CR18], [@CR20], [@CR23], [@CR30]\]. They reported that a statistically significant difference in mortality was confirmed between patients receiving non-Ca-based P binders and those receiving Ca-based P binders in their analysis of five clinical trials with a follow-up duration of 24 months \[[@CR9]\]. In contrast, in six trials with a follow-up duration of \<24 months, there was no significant differences in mortality between patients taking the two drugs \[[@CR10], [@CR11], [@CR13], [@CR18], [@CR19], [@CR30]\]. A benefit of non-Ca-based P binders might emerge over time. The duration of follow-up is set at 3 years in the LANDMARK study, which is considered to be sufficient to assess the effects of LC on cardiovascular mortality and morbidity compared to those of CC.

In a RCT, all-cause mortality was significantly lower in sevelamer treatment group compared with Ca-based P binder treatment group among elderly patients ≥65 years of age \[[@CR19]\]. Similarly, although LC treatment compared to standard therapy did not reduce mortality in all enrolled patients, LC was significantly associated with survival benefit in elderly patients with \>65 years of age \[[@CR37]\]. The mean age (68 years) of the patients enrolled into the LANDMARK study was older than that in previous RCTs, and the mean hemodialysis duration was longer.

Although the target number of enrolled patients was set at a total of 3000 patients (1500 in each treatment arm) because of the sample size assumption, in actuality, a total of 2309 patients (1154 in LC treatment, 1155 in CC treatment) were enrolled into the LANDMARK study. Despite the smaller number of patients than initially targeted, extension of follow-up period by 8 months could contribute to preservation of the statistical power. The number of enrolled patients in this study was still larger than that in any previous RCTs comparing the effect of non-Ca-based P binders with that of Ca-based P binders on mortality among dialysis patients.

The CAC score is a useful surrogate marker for cardiovascular mortality and morbidity in CKD patients \[[@CR5], [@CR14], [@CR30], [@CR36]\]. Block et al. reported that the baseline CAC score was a significant predictor of mortality in incident hemodialysis patients \[[@CR13]\]. Ca-based P binder use is likely to be involved not only in the progression of CAC \[[@CR10], [@CR12], [@CR33]\], but also in increased mortality \[[@CR13], [@CR14], [@CR19]\]. To date, there is limited information on differences in vascular calcification extent, CVE frequency, or mortality between dialysis patients receiving LC and those receiving Ca-based P binders. We will investigate whether LC improves the progression of CAC as compared with CC in the accompanying study (LANDMARK-SS).

Final results of the LANDMARK clinical trial would allow nephrologists to validly assess the clinically meaningful effects of ameliorated Ca burden by LC use on CVD mortality and morbidity in patients on hemodialysis.
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